ESC 2017

Area: Cardiology

Location: Barcelona, Spain

Date: August 26 to August 30

Description:

European Society of Cardiology Congress


Search in Scientific Content:
Date
Filters:
Anti-infla
10:47

Anti-inflammatory Against CV Events and Cancer

Presenter: Paul M. Ridker
Cardiology
Rivaroxaba
6:35

Rivaroxaban with or without aspirin in stable cardiovascular disease (COMPASS)

Presenter: John William Eikelboom
Cardiology
RACE 3 stu
6:18

RACE 3 study; The Routine versus Aggressive upstream rhythm Control for prevention of Early persistent atrial fibrillation in heart failure study

Presenter: Isabelle C Van Gelder
Cardiology
ALBATROSS
5:16

ALBATROSS and REMINDER trials

Presenter: Farzin Beygui
Cardiology
Mechanism
5:03

Mechanism for benefit of spironolactone in resistant hypertension in the PATHWAY-2 study

Presenter: Bryan Williams
Cardiology
Increased ...
5:05

Increased all-cause mortality with intensive blood-pressure control in patients with a baseline systolic blood pressure of ≥160 mmHg and a Lower Framingham risk score: a cautionary note from SPRINT

Presenter: Tzung-Dau Wang
Cardiology
Rivaroxaba
6:06

Rivaroxaban in stable peripheral or carotid artery disease

Presenter: Sonia Anand
Cardiology
Clinical E
5:38

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano
Cardiology
Catheter A
4:15

Catheter Ablation versus Standard conventional Treatment in patients with Left ventricular dysfunction and Atrial Fibrillation The CASTLE-AF trial

Presenter: Nassir F Marrouche
Cardiology
The long-t
5:01

The long-term follow-up of patients in the NIPPON (Nobori dual antiplatelet therapy as appropriate duration) study

Presenter: Masato Nakamura
Cardiology
Systolic B
2:09

Systolic Blood Pressure Variability and Major Adverse Outcomes in Patients with Atrial Fibrillation: The AFFIRM Study

Presenter: Marco Proietti
Cardiology
Determinat
5:14

Determination of the role of Oxygen in suspected Acute Myocardial Infraction

Presenter: Robin Hofman
Cardiology
Apixaban v
6:16

Apixaban vs. Heparin/Vitamin K Antagonist in Anticoagulation-naive Patients with Atrial Fibrillation Scheduled for Cardioversion: The EMANATE Trial

Presenter: Michael D. Ezekowitz
Cardiology
Investigat
6:11

Investigation of catheter-based renal denervation in patients with uncontrolled hypertansion in the absence of antihypertensive medications: Three-month results from the randomized, sham-controlled, proof of concept SPYRAL HTN-OFF MED trial

Presenter: Michael Böhm
Cardiology
Impact of
6:27

Impact of a 1- or 2-dose starting regimen of inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged LDL-C reduction over 1 year

Presenter: Kausik K Ray
Cardiology
The Left A
7:43

The Left Atrial Appendage Closure by Surgery study (LAACS)

Presenter: Jesper Park-Hansen
Cardiology
Atheroscle
9:37

Atherosclerosis and secondary cardiovascular disease prevention: inflammation and low density lipoprotein (LDL)-cholesterol

Presenter: Peter Libby
Cardiology
The Clinic...
5:25

The Clinician’s Perspective

Presenter: John Hakim
Cardiology
Managing c...
4:41

Managing cardiovascular outcomes in patients with type 2 diabetes – Where have we come from and where are we going? And Improving cardiovascular outcomes in patients with type 2 diabetes: our clinical experience with empagliflozin

Presenter: Darren McGuire
Cardiology
When to op
7:27

When to optimize heart failure treatment?

Presenter: Yuri Lopatin
Cardiology
Leading th
7:42

Leading the way to improved stroke prevention with NOACs: focus on AF patients undergoing non-surgical procedures and on subclinical AF

Presenter: Hein Heidbuchel
Cardiology
Recent res
4:23

Recent results in clinical trials of blood cholesterol lowering

Presenter: Rory Collins
Cardiology
A closer l
4:01

A closer look at glucose lowering agents cardiovascular safety results and current heart failure guidelines (TECOS)

Presenter: Anselm K Gitt
Cardiology
Modern man
9:08

Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure.

Presenter: David Fitchett
Cardiology
The eviden
7:24

The evidence supporting the use of FFR to guide percutaneous coronary intervention in stable and ACS patients.

Presenter: Pieter C. Smits
Cardiology
The cardio
12:38

The cardiologists' perspective on pulmonary hypertension.

Presenter: Stephan Rosenkranz
Cardiology
Identifyin
4:39

Identifying the aspirin patient: interactive case presentations.

Presenter: Giuseppe Biondi-Zoccai
Cardiology
Why wait t
2:58

Why wait to optimize treatment? / SPYRAL HTN OFF-MED Study P

Presenter: Michael Boehm
Cardiology
CANTOS Tri
2:21

CANTOS Trial - Anti-inflammatory Agent Against CV Events and Cancer

Presenter: Paul M. Ridker
Cardiology
PCSK9 inhi
5:45

PCSK9 inhibition across a wide spectrum of patients: for whom is it efficacious?

Presenter: G. Kees Hovingh
Cardiology
Lighting t
7:48

Lighting the way: a new path to manage hyperkalaemia (EBAC Accredited)

Presenter: Lars Lund
Cardiology
Redefining
4:00

Redefining anticoagulation in AF ablation: RE-CIRCUIT and RE-VERSE AD / Rewire your thinking on AF ablation: impact of uninterrupted dabigatran

Presenter: Hugh Calkins
Cardiology

ESC 2021

2021-08-27 - 2021-08-30
Online, Virtual

ACC 2021

2021-05-15 - 2021-05-17
Online, Virtual

ESH-ISH 2021

2021-04-11 - 2021-04-14
Online, Virtual

AHA 2020

2020-11-13 - 2020-11-17
Online, Virtual

ESC 2020

2020-08-29 - 2020-09-01
Online, Virtual

ESH 2020

2020-05-29 - 2020-06-01
Online, Virtual

ESC 2019

2019-08-31 - 2019-09-04
Paris, France

ACC 2019

2019-03-17 - 2019-03-19
New Orleans, LA, United States